Gland Pharma Signs Strategic CDMO Deal; 55 SKUs Could Generate $90–100 Million Annual Revenue
Gland Pharma Limited has announced a major strategic development in its contract development and manufacturing organisation (CDMO) business. The company has entered into a Manufacturing and Supply Agreement (MSA) with a leading global pharmaceutical company for the technology transfer, manufacturing and supply of a portfolio of sterile injectable products for international markets.
The agreement was announced by the company on August 9, 2026, and is expected to strengthen Gland Pharma’s long-term revenue visibility and expand its role as an integrated global CDMO partner.
Gland Pharma CDMO Partnership: Key Highlights
| Particular | Details |
|---|---|
| Company | Gland Pharma Limited |
| Exchange | BSE: 543245, NSE: GLAND |
| Agreement | Strategic Manufacturing and Supply Agreement |
| Partner | Global pharmaceutical company |
| Partner name | Not disclosed due to confidentiality |
| Geography | International markets |
| Products | Sterile injectable products |
| Number of SKUs | 55 |
| Manufacturing sites | 3 sites |
| Revenue commencement | Expected from CY2029 |
| Potential annual revenue | US$90–100 million |
| Technology transfer | Expected to be completed within 2 years |
| Scope for expansion | Additional products may be added |
55 Sterile Injectable Products Covered Under Agreement
Under the agreement, Gland Pharma will manufacture a portfolio of 55 SKUs across three of its manufacturing sites.
The product basket includes both oncology and non-oncology products, covering a range of injectable presentations such as:
- Vials
- Lyophilized (Lyo) products
- Ampoules
- Pre-filled syringes (PFS)
The portfolio includes both complex and conventional injectable formulations, allowing Gland Pharma to leverage its established capabilities in sterile injectables.
Potential Revenue of $90–100 Million Annually
One of the most important aspects of the agreement is its potential financial contribution.
Once all the products covered under the agreement are commercialized, Gland Pharma expects the portfolio to have an annualized revenue potential of approximately US$90–100 million.
However, the revenue opportunity is not expected to materialize immediately. Technology transfer activities are planned to be completed within approximately two years, with revenue generation expected to begin from calendar year 2029.
This provides the company with a significant medium- to long-term revenue visibility opportunity.
Full-Service CDMO Model
The agreement is not limited to manufacturing alone. Gland Pharma will provide a full-service CDMO solution covering several stages of the product lifecycle.
The scope includes:
- Technology transfer
- Process development
- Scale-up
- Validation
- Commercial manufacturing
- Quality support
- Regulatory support
- Long-term supply
This integrated approach allows Gland Pharma to act as a one-stop CDMO partner, supporting products from development and technology transfer through commercial manufacturing and supply.
Partnership Covers Global Markets
The agreement is an international arrangement, with the products intended for global markets.
The identity of the pharmaceutical company has not been disclosed because of confidentiality obligations. The company has described the counterparty as one of the leading global pharmaceutical companies.
For Gland Pharma, securing such a partnership highlights the confidence of global pharmaceutical companies in its capabilities in sterile injectable development, technology transfer, manufacturing and supply.
Scope for Additional Products
The initial agreement covers 55 SKUs, but the opportunity could expand further.
According to Gland Pharma, there is scope for adding more products to the partnership in the future. This could potentially increase the overall manufacturing opportunity and revenue contribution beyond the current agreement.
Management Commentary
Commenting on the partnership, Srinivas Sadu, Executive Chairman of Gland Pharma, said the collaboration demonstrates the confidence global pharmaceutical companies have in the company’s development, technology transfer, manufacturing and supply capabilities.
He highlighted that the agreement provides meaningful long-term revenue visibility, supports the expansion of Gland Pharma’s CDMO business and creates a foundation for future growth.
The company also plans to continue investing in the capabilities and capacity required to support the evolving requirements of its global partners.
Why This Deal Matters for Gland Pharma
The agreement is strategically important for Gland Pharma for several reasons.
1. Stronger CDMO Business
The partnership strengthens Gland Pharma’s position in the global CDMO market and supports its strategy of providing integrated development and manufacturing services to pharmaceutical companies.
2. Long-Term Revenue Visibility
With an estimated annualized revenue opportunity of US$90–100 million after commercialization of all products, the agreement provides meaningful long-term business visibility.
3. Diversified Product Portfolio
The 55-SKU portfolio includes oncology as well as non-oncology products and multiple injectable formats, reducing dependence on a single product or formulation.
4. Better Utilisation of Manufacturing Capabilities
Manufacturing will be carried out across three sites, allowing Gland Pharma to leverage its existing sterile injectable infrastructure and technical capabilities.
5. Potential for Further Expansion
The agreement allows for additional products to be added, creating the possibility of expanding the relationship over time.
Gland Pharma’s Global Injectable Business
Founded in 1978 in Hyderabad, Gland Pharma has evolved from a contract manufacturer of small-volume liquid parenteral products into a major injectable-focused pharmaceutical company.
The company has a presence across approximately 60 countries, including the United States, Europe, Canada, Australia and India.
Gland Pharma primarily operates through a CDMO and B2B business model, with capabilities spanning the development, manufacturing and marketing of sterile injectable products.
Its product capabilities include:
- Vials
- Ampoules
- Pre-filled syringes
- Lyophilized vials
- Dry powders
- Infusions
- Oncology products
- Ophthalmic solutions
The company has also pioneered Heparin technology in India.
What Investors Should Watch
The latest CDMO agreement is positive from a strategic and business-visibility perspective, but investors should also track the execution timeline.
The key milestones to monitor include:
- Progress of technology transfer
- Completion of validation activities
- Commercialization of the products
- Revenue ramp-up from CY2029
- Addition of new products to the agreement
- Capacity utilisation across the three manufacturing sites
- Actual revenue contribution versus the estimated US$90–100 million potential
Importantly, the US$90–100 million figure represents potential annualized revenue once all products are commercialized, rather than immediate revenue or guaranteed revenue in the current financial year.